HomeNB3 • FRA
add
Neurocrine Biosciences Inc
Previous close
€109.00
Day range
€108.75 - €108.75
Year range
€100.85 - €147.45
Market cap
11.57B USD
Avg Volume
31.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 627.70M | 21.84% |
Operating expense | 301.80M | 37.87% |
Net income | 103.10M | -30.20% |
Net profit margin | 16.43 | -42.69% |
Earnings per share | 1.69 | 9.74% |
EBITDA | 138.10M | -11.47% |
Effective tax rate | 36.59% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.08B | 4.31% |
Total assets | 3.72B | 14.37% |
Total liabilities | 1.13B | 10.75% |
Total equity | 2.59B | — |
Shares outstanding | 99.70M | — |
Price to book | 4.18 | — |
Return on assets | 9.03% | — |
Return on capital | 10.75% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 103.10M | -30.20% |
Cash from operations | 242.50M | 96.36% |
Cash from investing | -68.30M | 66.15% |
Cash from financing | -290.00M | -919.21% |
Net change in cash | -116.10M | -172.54% |
Free cash flow | 220.28M | 138.04% |
About
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Founded
1992
Headquarters
Website
Employees
1,800
